DGAP-News

Epigenomics AG: Epigenomics AG Announces H1 2014 and Q2 2014 Financial Results and Reports on Operational Highlights - Seite 4

- Relocation of Epigenomics' Berlin headquarters to be Completed: In
August, Epigenomics will complete the relocation of its Berlin
headquarters to a new facility within the city, which will be more
adept to efficiently house operations and allows for higher flexibility
for the Company's long-term planning.

Outlook

- The most significant milestone for Epigenomics is the timely roll-out
of the additional study with Epi proColon(R) to address FDA's
outstanding requests for the approval decision in the U.S.A.

- With regard to the earnings prognosis for the current business year,
there are no significant changes compared to the Company's statements
in the consolidated management report for 2013. Although, the expected
market approval for Epi proColon(R) in the U.S.A. is affected by a
delay, the earnings prognosis for 2014 remains unaltered, as the
initial guidance did not include any significant product revenues from
the U.S. market. According to the 2013 management report, Epigenomics
expects revenue in 2014 to slightly increase from 2013's level. Net
loss for 2014 is expected to be in the range of EUR 7.5 to 8.5 million.
In line with the expected net loss range, cash consumption for the
fiscal year 2014 is projected at a slightly increased level compared to
2013 in the range of EUR 7.0 to 8.0 million.

- The financial prognosis might be adjusted upon further conversions of
issued convertible notes or if redemptions of these occur. Given the
unexpected delay of the U.S. market approval, Epigenomics will
carefully consider and potentially execute all strategic options
available to the Company. These options explicitly include further
capital market transactions that would provide sufficient funds to the
Company until U.S. market approval for Epi proColon(R).


Further Information

Conference call for press and analysts

The full 6-Month Financial Report 2014 can be obtained from Epigenomics'
website at:
http://www.epigenomics.com/en/news-investors/investors/financial-reports/2
014.html

Epigenomics' management will host a conference call with web presentation
at 3pm CET/ 9am EST today, Tuesday, August 12, 2014. The conference call
will be held in English.

The dial-in numbers for the conference call are:

Dial-in number (within Germany): [phone]
Dial-in number (within the UK): [phone]
Dial-in number (within the U.S.): [phone]
Participants are kindly requested to dial in 10 minutes prior to the start
of the call.

The presentation accompanying the conference call and dial-in details for
the web presentation will be available on Epigenomics' website: